[Methods: scales, biological and clinical criteria]

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Context:

• Current methods for assessing depressive symptomatology in antidepressant trials lack objectivity.
• Regulatory authorities require high standardization for new drug registration, leading to reliance on established, albeit outdated, assessment tools.
• Existing assessment methods for new antidepressants are highly standardized but lack external validation.

Purpose:

• To highlight the limitations of current methods for assessing depressive symptomatology in antidepressant drug trials.
• To identify potential avenues for improving the assessment of new antidepressant efficacy.
• To address the need for more objective and validated measures in psychopharmacology research.

Summary:

• The assessment of depressive symptoms in clinical trials is hindered by the absence of reliable external validators.
• Standardization requirements by regulatory bodies favor conventional, less objective methods for evaluating antidepressants.
• Improvements are anticipated through the identification of objective depression validators and the development of drugs with novel mechanisms of action.

Impact:

• This research underscores the need for innovation in psychometric tools for depression assessment.
• Findings may guide the development of more accurate and objective clinical trials for antidepressant medications.
• Advances in this area could accelerate the approval and optimize the use of novel antidepressant therapies.